Congress Is Finally Asking the Question Employers Have Been Asking for Years

Prescription drug costs continue to climb, and the spotlight is once again turning toward one of healthcare’s most influential, yet least understood, players: pharmacy benefit managers (PBMs).

This week, Congress announced plans to advance legislation aimed at increasing oversight of PBMs and addressing concerns around transparency, pricing practices, and the role these organizations play in the prescription drug supply chain. While the outcome of these legislative efforts remains to be seen, one thing is clear: the conversation around prescription drug costs has reached a national level.

For many employers, however, this isn’t a new conversation.

The Problem Didn’t Start in Washington

Self-funded employers have been navigating rising pharmacy costs for years. Specialty medications continue to account for a disproportionate share of healthcare spending, while new therapies, provider consolidation, and evolving rebate structures have made pharmacy benefits increasingly difficult to manage.

As costs rise, many employers are left asking the same questions:

• Why are prescription drug costs increasing so quickly?
• Where is the money actually going?
• Are employees receiving the most affordable, clinically appropriate medications?
• What options exist beyond simply shifting more costs to employees?

These are the questions Congress is now beginning to examine on a broader scale.

Transparency Is Becoming the Priority

Regardless of how legislation ultimately unfolds, one trend is becoming increasingly clear: transparency is no longer optional.

Employers want greater visibility into how pharmacy dollars are spent. They want to understand the factors driving costs, evaluate whether existing strategies are producing meaningful results, and identify opportunities to improve both financial performance and employee access to care.

That shift is changing how organizations evaluate their pharmacy strategies.

Rather than focusing solely on negotiated discounts or rebate arrangements, many employers are looking for solutions that emphasize transparency, clinical appropriateness, and better health outcomes while helping reduce unnecessary spending.

Employers Don’t Have to Wait

Legislative reform can take time. Even if new policies are enacted, meaningful changes across the healthcare system rarely happen overnight.

Fortunately, employers don’t need to wait for federal action before taking steps to better manage prescription drug spending.

Organizations can begin by evaluating where their highest pharmacy costs originate, identifying opportunities to improve access to lower-cost alternatives when clinically appropriate, and partnering with organizations that prioritize patient advocacy and transparent solutions.

The goal isn’t simply to spend less. It’s to spend smarter while ensuring employees receive the medications they need.

Looking Ahead

Congressional scrutiny of PBMs reflects a growing recognition that prescription drug affordability is a challenge affecting employers, employees, and families across the country.

Whether new legislation ultimately reshapes the pharmacy landscape or not, one thing is unlikely to change: employers will continue searching for strategies that improve transparency, support employees, and bring greater predictability to healthcare spending.

The organizations that begin evaluating those strategies today will be better positioned to navigate whatever changes come tomorrow.